Prevalence of vulvovaginal candidiasis in females in the reproductive age group


  • Meena Salvi Department of Obstetrics and Gynecology, Prime Medical Centre, Sharjah attached with Prime Hospital, Dubai, U.A.E



High vaginal swab (HVS), Intrauterine contraceptive device (IUCD), Oral contraceptive pills (OC pills), Prevalence, Reproductive age, Vulvovaginal candidiasis (VVC)


Background: Vulvovaginal candidiasis (VVC) is a common infection among reproductive age group females. The objective of present study is to determine the prevalence of vulvovaginal candidiasis, its distribution and association of risk factors among reproductive age group females, attending the outpatient department of obstetrics and gynaecology of our Prime Medical Centre, Sharjah attached with Prime Hospital, Dubai, United Arab Emirates (UAE).

Methods: It was cross-sectional descriptive study over a period of six months. Patients who came to our outpatient department with complains of vaginal discharge and itching in reproductive age group were included in this study. Patients characteristics i.e. age, parity, risk factors like diabetes, pregnancy, use of oral contraceptive pills (OCPills) and intrauterine contraceptive device (IUCD) were noted. High vaginal swabs (HVS) were collected and sent for culture. Candida positive cases were noted, and results were analyzed.

Results: A total of 224 high vaginal swabs were collected. Prevalence of vulvovaginal candidiasis was found to be 31.6%. It was found more in 26-30 years age group and multiparous women. Previous history of candidiasis and diabetes were the commonest risk factors. Frequency of C. albicans was more (76.05%) than non-albicans candida (23.94%).

Conclusions: Present study concluded that vulvovaginal candidiasis is more prevalent in reproductive age group females, therefore a routine high vaginal swab culture must be performed in every woman presenting with vaginal discharge and itching for correct diagnosis. Women should be educated on clinical symptoms.


Freshwater D, Masiln-Prothero S, Blackwell’s Nursing dictionary, Inc Blackwell publishing Ltd 2nd ed; 2005:642.

Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. Annals Emerg Med. 2015;66(5):526-8.

McClelland RS, Richardson BA, Hassan WM, Graham SM, Kiarie J, Baeten JM, et al. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis. 2009;199(12):1883-90.

Thulkar J, Kriplani A, Agarwal N, Vishnubhatla S. Aetiology and risk factors of recurrent vaginitis and its association with various contraceptive methods. Ind J Med Res. 2010;131(1).

Singh SI. Treatment of vulvovaginal candidiasis. Clin Rev CPJ/RPC. 2003;136(9):26-30.

Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clinical Microbio Rev. 2010;23(2):253-3.

Geiger AM, Foxman B, Sobel JD. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C. glabrata and no Candida. Genitourin Med. 1995;71(5):304-7.

Berg AO, Heidrich FE, Fihn SD, Bergman JJ, Wood RW, Stamm WE, et al. Establishing the cause of genitourinary symptoms in women in a family practice: comparison of clinical examination and comprehensive microbiology. JAMA. 1984;251(5):620-5.

Kalia N, Singh J, Sharma S, Kamboj SS, Arora H, Kaur M. Prevalence of vulvovaginal infections and species-specific distribution of vulvovaginal candidiasis in married women of north india. Int J Curr Microbiol App Sci. 2015;4(8):253-66.

Kwawukume EY, Arhin RA. Vulvovaginitis. In: Kwawukume EY, Emuveyan EE, eds. Comprehensive Gynaecology in the Tropics. 1st ed. Dansoman: Asante and Hittscher Printing Press Limited; 2002:72-74.

Mirza NB, Nsanze H, D’Costa LJ, Piot P. Microbiology of vaginal discharge in Nairobi, Kenya. Br J Vener Dis. 1983;59:186-8.

Otero L, Palacio V, Carreno F, Mendez FJ, Vazquez F. Vulvovaginal candidiasis in female sex workers. Int J STD AIDS.1998;9(9):526-30.

Ugwa EA. Vulvovaginal Candidiasis in Aminu Kano Teaching Hospital, North‑West Nigeria: Hospital‑Based Epidemiological Study. Annals Med Health Sci Res. 2015;5(4):274-8.

Yadav K, Prakash S. Prevalence of vulvovaginal candidiasis in pregnancy. Global J Med Med Sci. 2016;4(1):108-6.

Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol. 1991;165(4):1168-76.

Kanagal DV, Vineeth VK, Kundapur R, Shetty H, Rajesh A. Prevalence of vaginal candidiasis in pregnancy among coastal south Indian women. J Womens Health Issues Care. 2014;3(6):2.

Akah PA, Nnamani CE, Nnamani PO. Prevalence and treatment outcome of vulvovaginal candidiasis in pregnancy in a rural community in Enugu State, Nigeria. J Med Med Sci. 2010;1(10):447-52.

Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985;152(7):924-35.

Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care. 2007;30(2):312-7.

Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Family Physician. 2000;61(11):3306-12.






Original Research Articles